Q4 FY20 Earnings Call August 4, 2020

Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation regarding CSI’s strategy; growth; future financial measurements and investments; product development plans, milestones and introductions; geographic expansion; clinical trials and evidence; professional education efforts; market estimates and opportunities; and developments related to the COVID-19 pandemic are forward-looking statements. These statements involve risks and uncertainties that could cause results differ materially from those projected, including, but not limited to, those described in CSI’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly and annual reports. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this presentation. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation. The forward-looking statements contained in this presentation are made only as of the date of this presentation, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances. FINANCIAL INFORMATION This presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by CSI’s independent registered accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences, which may be material.

Q4 Revenues of $42.5 Million 38% Decrease ($ in millions) Revenues US Peripheral revenue declined 36% US Peripheral, US Coronary, US Coronary revenue $30.6 $9.8 declined 44% International, International decreased 17% $2.1 US Peripheral US Coronary International

Q4 FY20 Financial Results ($ in millions) Worldwide Peripheral Revenue Worldwide Coronary Revenue $48.3 $45.5 $47.6 $20.8 $42.6 $20.0 $19.0 $18.5 $30.6 36% $11.9 41% decline decline WW in Q4 WW in Q4 due to due to Covid-19 Covid-19 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Gross Margin Cash and Marketable Securities $232.2 80.3% 80.4% 79.9% 80.0% 76.2% $122.7 $105.0 $109.4 $107.3 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20

Q4 FY20 Highlights Financial Operational - Peripheral Operational – Coronary Other Revenues -37.6% vs. LY • Use of low profile peripheral • Launching next gen coronary • Sold 14,500 OAS units offerings including Exchangeable OAS will facilitate cath lab • Over 1,200 medical Gross Margin 76.2% and Radial are resonating as access in early FY21 professionals attended CSI physicians seek to reduce • Continued adoption of coronary virtual education programs SGA Expenses -20.5% to $35.0M procedure time and bleeding toolkit featuring OAS with • REACH Peripheral Radial complications associated with GlideAssist, 1.0mm Sapphire Study data presented at R&D Expenses +25.1% to $11.8M traditional femoral access angioplasty balloons, Teleport NCVH in July 2020 • Targeting launch of WIRION Microcatheter and nitinol • Targeting first in human Net Loss of $(15.2)M EPD in early FY21 ViperWire with Flex Tip drove experience for pVAD device in • Targeting launch of peripheral over $500 of incremental FY21 Cash and marketable securities support products in 2H FY21 revenue for every coronary • PTAB invalidated 3 key IVL increased to $232.2M • Added physician finder to OAS sold in Q4 patents www.standagainstamputation.com, • Anticipate CE Mark in FY21 • Review of lower extremity No long-term debt 3,200 patients clicked through to • ECLIPSE enrollment to restart endovascular code set is on identify physicians treating when reasonable the October 2020 CPT patients during pandemic Editorial Panel agenda

Fiscal 2021 First Quarter Guidance For the fiscal 2021 first quarter ending September 30, 2020, CSI anticipates: • Revenue of $55 million to $58 million, representing sequential revenue growth compared to the fourth quarter of fiscal 2020 of 29% to 36%; • Gross profit as a percentage of revenues in the 76% to 77% range; and • Operating expenses in a range of $50 to $52 million.

Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2020 Cardiovascular Systems, Inc. CSII OrbusNeich®, Teleport® and Sapphire® are trademarks of OrbusNeich Medical, Inc. Cardiovascular Systems, Inc. For more information: www.csi360.com @csi360